E-resources
Peer reviewed
-
Yamaguchi, Yuki; Nishizono, Naozumi; Kobayashi, Daisuke; Yoshimura, Teruki; Wada, Keiji; Kobayashi, Kenichi; Oda, Kazuaki
Bioorganic & medicinal chemistry letters, 04/2023, Volume: 86Journal Article
Display omitted Cytochrome P450 2A6 (CYP2A6) inhibitors are expected to be suitable as smoking cessation aids and for cancer prevention. Because the typical coumarin-based CYP2A6 inhibitor methoxsalen also inhibits CYP3A4, unintended drug-drug interactions are still a concern. Therefore, the development of selective CYP2A6 inhibitors is desirable. In this study, we synthesized coumarin-based molecules, determined the IC50 values for CYP2A6 inhibition, verified the possibility of mechanism-based inhibition, and compared the selectivity for CYP2A6 versus CYP3A4. The results demonstrated that we developed CYP2A6 inhibitors that were more potent and selective than methoxsalen.
